Document is current

Any future updates will be listed below

A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)

Crossref DOI link: https://doi.org/10.1007/s10147-017-1140-z

Published Online: 2017-05-19

Published Print: 2017-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark